UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,690	04/26/2005	Kirvin L. Hodge	18028-PCTUS	5946
	7590 07/22/200 gement Company. LLC		EXAMINER	
LEGAL DEPA	RTMENT	WEDDINGTON, KEVIN E		
930 CLOPPER GAITHERSBU	RGAD RG, MD 20878		ART UNIT	PAPER NUMBER
			1614	
			MAIL DATE	DELIVERY MODE
			07/22/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Applicat	ion No.	Applicant(s)		
Office Action Summary		10/532,6	390	HODGE ET AL.		
		Examine	er	Art Unit		
		KEVIN V	VEDDINGTON	1614		
Period fo	The MAILING DATE of this commun or Reply	ication appears on th	ne cover sheet with	the correspondence ac	ddress	
A SHO WHIC - Exter after - If NO - Failui Any r	ORTENED STATUTORY PERIOD F CHEVER IS LONGER, FROM THE M Isions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comn period for reply is specified above, the maximum st- et to reply within the set or extended period for reply eply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	IAILING DATE OF T of 37 CFR 1.136(a). In no e nunication. atutory period will apply and will, by statute, cause the ap	THIS COMMUNICA event, however, may a reply will expire SIX (6) MONTHS oplication to become ABANI	TION.  be timely filed  from the mailing date of this of DONED (35 U.S.C. § 133).		
Status						
2a)⊠	Responsive to communication(s) file This action is <b>FINAL</b> . Since this application is in condition closed in accordance with the practi	2b)⊡ This action is for allowance excep	ot for formal matters	•	e merits is	
Dispositi	on of Claims					
5)□ 6)⊠ 7)⊠ 8)□ Applicati	Claim(s) <u>2-8</u> is/are pending in the ap 4a) Of the above claim(s) is/a Claim(s) is/are allowed. Claim(s) <u>2-5 and 8</u> is/are rejected. Claim(s) <u>6 and 7</u> is/are objected to. Claim(s) are subject to restrict on Papers The specification is objected to by th	re withdrawn from c				
10)	The specification is objected to by the The drawing(s) filed on is/are: Applicant may not request that any objected to ath or declaration is objected to the specification is objected to by the specification is objected to the specification is ob	a) accepted or bection to the drawing(s) the correction is requ	be held in abeyance. ired if the drawing(s)	. See 37 CFR 1.85(a). is objected to. See 37 C		
Priority u	ınder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
2)  Notic 3) Inforr	t <b>(s)</b> e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (F nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	PTO-948)	Paper No(s)/M	nmary (PTO-413) lail Date mal Patent Application		

Art Unit: 1614

Claims 2-8 are presented for examination.

Applicants' request for reconsideration filed April 21, 2009 has been received and entered.

## Claim Objections

Claims 6 and 7 are again objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 2-5 and 8 are again rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

This is a written description rejection.

A lack of adequate written description issue arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus

because it would not "reasonably lead" those skilled in the art to any particular species); In re Ruschig, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967).

Page 3

An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics.

In particular, the specification as original filed fails to provide sufficient written bases of any of the agents demonstrating wherein possession of use of the broad term:

diabetes. The mere fact that Applicant may have discovered the type 1 diabetes and type 2 diabetes were effectively treated with the said active agents is not sufficient to claim the entire genus.

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.

A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is

substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]."

Applicants' remarks regarding the third type of diabetes, "gestational diabetes" is supported by their instant specification and that type 2 diabetes and gestational diabetes are connected are not persuasive since "gestational diabetes" is a type of diabetes that starts during pregnancy. Nowhere in applicants' specification there is support showing the connection between type 2 diabetes and gestational diabetes. Also the instant specification does not even talk about gestational diabetes, so how can they have provided support for the broad term "diabetes" which includes "gestational diabetes" without any mention of "gestational diabetes".

The rejection made under 35 USC 112, first paragraph (Written Description) is adhered to.

Claims 2-5 and 8 are not allowed.

## Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Application/Control Number: 10/532,690 Page 5

Art Unit: 1614

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN WEDDINGTON whose telephone number is (571)272-0587. The examiner can normally be reached on 12:30 pm - 9:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571)272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

KEVIN WEDDINGTON Primary Examiner Art Unit 1614 Application/Control Number: 10/532,690 Page 6

Art Unit: 1614

/KEVIN WEDDINGTON/ Primary Examiner, Art Unit 1614